The Middle East asthma treatment market is projected to grow from USD 1.77 billion in 2025 to nearly USD 2.94 billion by 2035, expanding at a CAGR of 5.21%, driven by rising respiratory disorders, urban pollution, and improved access to advanced therapies.

Middle East Asthma Treatment Market Statical Scope

Advanced inhalation therapies, the adoption of digital health , and the expansion of healthcare are the main drivers of the Middle East market. Early diagnosis and treatment adherence are being supported by growing funding and awareness campaigns. The market is expanding due to the increasing prevalence of respiratory illnesses brought on by climate change.

The market is driven by growing healthcare investments, an increase in respiratory disorders, and urbanization. Growing awareness of chronic respiratory diseases and better healthcare infrastructure are driving market expansion. Long-term growth is also being supported by the increasing use of sophisticated inhalation treatments.

Middle East Asthma Treatment Market Share, By Drug Class, 2025 (%)

• Anti-inflammatory- Anti-inflammatory drugs lead the market with a 44% share driven by rising respiratory disease burden and environmental facto
• Bronchodilators- Bronchodilators account for a significant portion, with 31% of the market share driven by the need for immediate symptom management.
• Combination Therapy- Combination therapy holds a notable segment of 25% of the market driven by increasing adoption of integrated treatment options.

Middle East Asthma Treatment Market Share, By Product, 2025 (%)

• Inhalers- Inhalers dominate the market with a 63% share driven by improving healthcare infrastructure and patient awareness.
• Nebulizers- Nebulizers represent 37% of the market share driven by demand in acute and emergency care settings.

Middle East Asthma Treatment Market Share, By Route of Administration, 2025 (%)

• Inhaled- Inhaled medication is the dominant route, accounting for 71% of the market share driven by higher treatment efficiency and faster results.
• Oral- Oral administration holds 21% of the market driven by ease of use in routine medication.

Top Companies in the Middle East Asthma Treatment Market

• Teva Pharmaceutical Industries Ltd.
• GSK plc
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Sanofi.
• Koninklijke Philips N.V.
• BD
• Covis Pharma

Segments Covered in the Report

By Drug Class

• Anti- inflammatory
• Bronchodilators
• Combination Therapy

By Product

• Inhalers
• Nebulizers

By Route of Administration

• Oral
• Inhaled
• Others